Vaxcyte, Inc.
US ˙ NasdaqGS ˙ US92243G1085

SecurityPCVX / Vaxcyte, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership2,865,318 shares
Latest Disclosed Value $ 166,503,629
D. E. Shaw & Co., Inc. reports 21.09% decrease in ownership of PCVX / Vaxcyte, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 2,865,318 shares of Vaxcyte, Inc. (US:PCVX) valued at $166,503,629 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 3,631,053 shares of Vaxcyte, Inc.. This represents a change in shares of -21.09% during the quarter. The current value of the position is $134,469,374 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VAXCYTE COM 92243G108 2,865,318 -765,735 -21.09 166,504 -0.62 0.0735
2026-02-17 2025-12-31 13F VAXCYTE COM 92243G108 3,631,053 -659,737 -15.38 167,537 8.40 0.0918
2025-11-14 2025-09-30 13F VAXCYTE COM 92243G108 4,290,790 1,202,340 38.93 154,554 53.93 0.0872
2025-08-14 2025-06-30 13F VAXCYTE COM 92243G108 3,088,450 2,220,559 255.86 100,406 206.38 0.0712
2025-05-15 2025-03-31 13F VAXCYTE COM 92243G108 867,891 92,238 11.89 32,772 -48.39 0.0292
2025-02-14 2024-12-31 13F VAXCYTE COM 92243G108 775,653 352,155 83.15 63,495 31.20 0.0466
2024-11-14 2024-09-30 13F VAXCYTE COM 92243G108 423,498 193,291 83.96 48,393 178.41 0.0415
2024-08-14 2024-06-30 13F VAXCYTE COM 92243G108 230,207 -137,042 -37.32 17,383 -30.71 0.0163
2024-05-15 2024-03-31 13F VAXCYTE COM 92243G108 367,249 -71,062 -16.21 25,087 -8.86 0.0215
2024-02-14 2023-12-31 13F VAXCYTE COM 92243G108 438,311 -100,073 -18.59 27,526 0.29 0.0241
2023-11-14 2023-09-30 13F VAXCYTE COM 92243G108 538,384 -274,528 -33.77 27,447 -32.39 0.0287
2023-08-14 2023-06-30 13F VAXCYTE COM 92243G108 812,912 18,005 2.27 40,597 36.26 0.0415
2023-05-15 2023-03-31 13F VAXCYTE COM 92243G108 794,907 -177,414 -18.25 29,793 -36.10 0.0319
2023-02-14 2022-12-31 13F VAXCYTE COM 92243G108 972,321 972,321 46,623 0.0515
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.